| Autor: |
Ghose A; Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK.; Department of Medical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood HA6 2RN, UK.; Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK.; Division of Research, Academics and Cancer Control, Saroj Gupta Cancer Centre and Research Institute, Kolkata 700063, India., Gullapalli SVN; School of Biosciences Education, Faculty of Life Sciences and Medicine, King's College London, London WC2R 2LS, UK., Chohan N; Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK., Bolina A; Department of Haematology, Clatterbridge Cancer Centre Liverpool, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool L7 8YA, UK., Moschetta M; Novartis Institutes for BioMedical Research, 4033 Basel, Switzerland., Rassy E; Department of Medical Oncology, Gustave Roussy Institut, 94805 Villejuif, France., Boussios S; Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK.; School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London WC2R 2LS, UK.; AELIA Organization, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece. |
| Abstrakt: |
The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous disease has distinguishable etiology and molecular biology. Next-generation sequencing changed clinical diagnostic testing, allowing assessment of multiple genes, simultaneously, in a faster and cheaper manner than sequential single gene analysis. Technologies of proteomics, such as mass spectrometry (MS) and protein array analysis, have advanced the dissection of the underlying molecular signaling events and the proteomic characterization of OC. Proteomics analysis of OC, as well as their adaptive responses to therapy, can uncover new therapeutic choices, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is an urgent need to better understand how the genomic and epigenomic heterogeneity intrinsic to OC is reflected at the protein level, and how this information could potentially lead to prolonged survival. |
